Related Experiment Video
Updated: Apr 20, 2026
07:57
Assessing Whole-Body Lipid-Handling Capacity in Mice
Published on: November 24, 2020
5.0K
Pediatric lipid management: an earlier approach
Justin P Zachariah1, Philip K Johnson1
1Department of Cardiology, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.
Endocrinology and Metabolism Clinics of North America
|November 30, 2014
Summary
The National Heart, Lung and Blood Institute guidelines focus on preventing cardiovascular disease (CVD) in children through healthy behaviors and targeted treatments. These strategies aim to reduce future CVD events by addressing root causes in pediatric populations.
Area of Science:
- Pediatric Cardiology
- Public Health
- Preventive Medicine
Background:
- Cardiovascular disease (CVD) poses a significant long-term health risk.
- Current guidelines emphasize risk factor reduction in children.
- Genetic dyslipidemias require specific attention in pediatric populations.
Purpose of the Study:
- To summarize the National Heart, Lung, and Blood Institute Expert Panel Integrated Guidelines for CVD prevention in children.
- To highlight the shift towards addressing root causes of CVD in pediatric care.
- To outline strategies for primary and secondary prevention of CVD events in youth.
Main Methods:
- Review of the National Heart, Lung, and Blood Institute Expert Panel Integrated Guidelines.
- Analysis of recommendations for lifestyle modifications and pharmacotherapy.
- Focus on screening and treatment protocols for pediatric dyslipidemias.
Main Results:
- Guidelines promote universal healthy behaviors for all children.
- Specific screening and treatment are recommended for genetic dyslipidemias.
- Lipid pharmacotherapy is reserved for highest-risk children.
Conclusions:
- The guidelines position children centrally in future CVD prevention efforts.
- Pediatric providers can focus on eliminating CVD causes, not just trimming risk factors.
- Integrated strategies aim to reduce the burden of cardiovascular disease from childhood.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
373
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
373
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
393
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
393
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
518
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
518
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
895
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
895
01:24Overview of Lipid Metabolism
7.3K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.3K
01:26Atherosclerosis III: Management
650
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
650